Wedbush Rates Kiniksa Pharmaceuticals International (KNSA) buy

On June 29, 2026, Wedbush analyst David Nierengarten reiterated his buy rating on KNSA, setting a price target of $72. This move comes as the stock traded around $59.2 on Monday.

Other Institutional Activity in KNSA

FMR LLC significantly increased its holdings in KNSA by 5,180,837 shares, bringing its total to 6,823,700 shares valued at approximately $328.6 million. Rubric Capital Management LP also added to its position, increasing by 421,347 shares to a total of 3,750,000 shares worth about $180.6 million. Meanwhile, Vanguard Portfolio Management LLC opened a new position with 1,766,268 shares valued at $85.0 million. In contrast, Acadian Asset Management LLC reduced its holdings by 376,730 shares, ending with 1,336,313 shares valued at $64.3 million.

Kiniksa Pharmaceuticals International, plc Stock Down 19.2%

Shares of KNSA traded near $59.2 on Monday. The company's recent analyst activities and institutional movements reflect an ongoing interest in its potential performance.

Insider Buying and Selling at Kiniksa Pharmaceuticals International, plc

Several insider transactions were reported for KNSA. On June 1, 2026, Chairman and CEO Sanj Patel sold 900,000 shares. Richard Levy and Thomas Malley both made purchases of 2,799 and 12,158 shares, respectively, on May 29, 2026.

Analysts Set New Price Targets

On June 29, 2026, Wedbush maintained its buy rating with a $72 price target on KNSA. Canaccord Genuity and Citigroup also maintained buy ratings with targets of $64 and $60, respectively, on April 29, 2026. The consensus among analysts remains positive, with a buy recommendation and a mean target price reflecting optimism about the stock's future.

Bottom Line

Wedbush's reiteration of a buy rating and a $72 price target on KNSA underscores analyst confidence. Investors closely watch these ratings to gauge potential stock performance, though the 13F filings and insider activity provide a backward-looking view of institutional sentiment.